Resveratrol impacts health in patients with diabetes mellitus and other metabolic conditions
DOI:
https://doi.org/10.12775/JEHS.2022.12.11.045Keywords
resveratrol, diabetes, metabolismAbstract
Background
Resveratrol is a polyphenol with many properties, including activity against glycation, oxidative stress, inflammation, neurodegeneration, carcinogenesis and aging. It appears to be a promising compound for the prevention and treatment of metabolic diseases. The aim of this review is to summarize the results of the latest clinical trials that concern effects of resveratrol in diabetes mellitus type 1 and 2 and its complications - diabetic foot ulcers, diabetic nephropathy and non-alcoholic fatty liver disease.
Aim of the study
Based on in vitro studies and animal models, it has been observed that resveratrol reverses the factors causing premature death: obesity, hypertension, and hyperlipidemia. Because of its anti-inflammatory, antioxidant, cardioprotective and blood lowering glucose effects, it appears to be a promising compound for the treatment of metabolic conditions. The review presents different clinical trials concerning the efficiency of resveratrol supplementation in patients with diabetes mellitus and metabolic syndrome and their complications. Most studies focused on assessing the effect of resveratrol supplementation as an adjunctive treatment of diabetes mellitus type 2 and in this group of patients it gave the best results causing reduction of fasting glucose levels, fasting insulin concentration, insulin resistance and improvement of insulin sensitivity and lipid profiles.
Conclusions
Resveratrol remains a potential drug in the treatment of metabolic diseases like diabetes mellitus. However, the results of the conducted trials are inconscient. More research is needed to confirm the effectiveness of resveratrol supplementation in treating diabetes, its complications and other metabolic conditions.
References
Meng T, Xiao D, Muhammed A et al. Anti-Inflammatory Action and Mechanisms of Resveratrol. Molecules. 2021; 26(1): 229. https://doi.org/10.3390/molecules26010229.
Kuršvietienė L, Stanevičienė I, Mongirdienė A et al. Multiplicity of effects and health benefits of resveratrol. Medicina (Kaunas). 2016; 52(3): 148-55. https://doi.org/10.1016/j.medici.2016.03.003.
Zhang LX, Li CX, Kakar MU et al. Resveratrol (RV): A pharmacological review and call for further research. Biomed Pharmacother. 2021; 143: 112164. https://doi.org/10.1016/j.biopha.2021.112164.
Pangeni R, Sahni JK, Ali J et al. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014; 11(8): 1285-98. https://doi.org/10.1517/17425247.2014.919253.
IDF Diabetes Atlas 2021. 10th edition. Available on www.diabetesatlas.org
Harding JL, Pavkov ME, Magliano DJ et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019; 62(1): 3-16. https://doi.org/10.1007/s00125-018-4711-2.
Movahed A, Raj P, Nabipour I et al. Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial. Nutrients. 2020; 12(1): 161. https://doi.org/10.3390/nu12010161.
Brasnyó P, Molnár GA, Mohás M et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 201; 106(3): 383-9. https://doi.org/10.1017/S0007114511000316.
Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012; 32(7): 537-41. https://doi.org/10.1016/j.nutres.2012.06.003.
Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013; 72: 69-82. https://doi.org/10.1016/j.phrs.2013.03.011.
Goh KP, Lee HY, Lau DP et al. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab. 2014; 24(1): 2-13. https://doi.org/10.1123/ijsnem.2013-0045.
Zare Javid A, Hormoznejad R, Yousefimanesh HA et al. The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis. Phytother Res. 2017; 31(1): 108-114. https://doi.org/10.1002/ptr.5737.
Thazhath SS, Wu T, Bound MJ et al. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. Am J Clin Nutr. 2016;103(1):66-70. https://doi.org/10.3945/ajcn.115.117440.
Bo S, Ponzo V, Ciccone G et al.. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016; 111 :896-905. https://doi.org/10.1016/j.phrs.2016.08.010.
Timmers S, de Ligt M, Phielix E et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2016 Dec;39(12):2211-2217. https://doi.org/10.2337/dc16-0499.
Imamura H, Yamaguchi T, Nagayama D et al. Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus. Int Heart J. 2017; 58(4): 577-583. https://doi.org/10.1536/ihj.16-373.
Khodabandehloo H, Seyyedebrahimi S, Esfahani EN et al. Resveratrol supplementation decreases blood glucose without changing the circulating CD14+CD16+ monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Nutr Res. 2018; 54: 40-51. https://doi.org/10.1016/j.nutres.2018.03.015.
Hoseini A, Namazi G, Farrokhian A et al. The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food Funct. 2019; 10(9):6042-6051. https://doi.org/10.1039/c9fo01075k.
Abdollahi S, Salehi-Abargouei A, Toupchian O et al. The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial. Phytother Res. 2019; 33(12): 3153-3162. https://doi.org/10.1002/ptr.6487.
Mahjabeen W, Khan DA, Mirza SA. Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complement Ther Med. 2022 Jun;66:102819. https://doi.org/10.1016/j.ctim.2022.102819.
Poulsen MM, Vestergaard PF, Clasen BF et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013; 62(4): 1186-95. https://doi.org/10.2337/db12-0975.
Méndez-del Villar M, González-Ortiz M, Martínez-Abundis E et al. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014; 12(10): 497-501. https://doi.org/10.1089/met.2014.0082.
Poulsen MK, Nellemann B, Bibby BM et al. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes Obes Metab. 2018; 20(10): 2504-2509. https://doi.org/10.1111/dom.13409.
Kantartzis K, Fritsche L, Bombrich M et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018; 20(7): 1793-1797. https://doi.org/10.1111/dom.13268.
Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015; 114(5): 796-803. https://doi.org/10.1017/S0007114515002433.
Çetinkalp Ş, Gökçe EH, Şimşir I et al. Comparative Evaluation of Clinical Efficacy and Safety of Collagen Laminin-Based Dermal Matrix Combined With Resveratrol Microparticles (Dermalix) and Standard Wound Care for Diabetic Foot Ulcers. Int J Low Extrem Wounds. 2021; 20(3): 217-226. https://doi.org/10.1177/1534734620907773.
American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25Suppl. 1: S85–93.
Jungman E. Prevention and Treatment of Diabetic Nephropathy in Older Patients. Drugs & Aging. 2003; 20: 419-435. https://doi.org/10.2165/00002512-200320060-00002.
Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B et al. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 2019; 45(1): 53-59. https://doi.org/10.1016/j.diabet.2018.05.010.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Emilia Nowak, Dominika Psiuk, Agata Rocka, Natalia Dycha, Patryk Jasielski, Faustyna Jasielska, Dominika Madras, Ewelina Rocka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 389
Number of citations: 0
